Heart disease does not wait. Neither do the doctors treating it. That urgency is now showing up in the numbers.
The global cardiac marker testing market is projected to grow from approximately $5.54 billion in 2026 to $9.06 billion by 2031, according to a new report by MarketsandMarkets™. That is a significant jump in just five years, and the drivers behind it are not hard to understand.
At the centre of this growth is one clear shift in how healthcare works: speed matters more than ever, and the tools being used to detect cardiac events are getting faster, more accurate, and increasingly available outside the traditional hospital laboratory setting.
Why the Market is Growing
Three forces are pushing this market forward simultaneously.
The first is the sheer scale of cardiovascular disease globally. Ageing populations, combined with rising rates of obesity and diabetes, have made heart-related conditions one of the most pressing burdens on healthcare systems across the world. More patients presenting with cardiac symptoms means more demand for the tests used to detect them quickly and accurately.
The second is the growing pressure on emergency care settings to deliver results faster. In cardiology, time directly affects outcomes. When a patient arrives with chest pain, clinicians cannot afford to wait hours for a laboratory result. Cardiac marker testing, which measures proteins like troponin released into the blood when the heart is under stress, gives emergency teams the information they need to act decisively. That kind of clinical urgency is driving hospitals and health systems to invest more heavily in this space.
The third factor is the broader shift toward decentralised healthcare. More care is moving away from large centralised hospitals and toward community clinics, urgent care centres, and even home-based settings. That shift requires diagnostic tools that can travel with the patient, not the other way around.
Point-of-Care Testing Leads the Way
Of all the segments within this market, point-of-care testing is expected to grow the fastest over the forecast period. The reason is straightforward: it puts diagnostic capability directly where the patient is, whether that is an emergency department, an ambulance, a rural clinic, or a critical care unit.
The appeal is immediate results without the wait that comes with sending samples to a central lab. In emergency settings, that difference can be the difference.
Technology is Raising the Bar
Beyond speed, the overall quality of cardiac diagnostics is improving too, kind of steadily. High-sensitivity biomarker tests are now able to spot signs of cardiac stress at much lower thresholds compared to the older assays. And those multiplex platforms let clinicians check for several markers in one go, instead of doing separate runs one by one.
Meanwhile, laboratory automation cuts down on human errors, and it also trims the processing time. Plus there is integration with digital health systems, so results move straight into the clinical charts, supporting quicker and more well-informed decisions right at the bedside.
Reagents and Kits Dominate Today’s Market
On the product side, reagents and kits held the largest market share in 2026. This is consistent with the expanding network of diagnostic laboratories worldwide and the ongoing demand for consumables that fuel daily testing volume. As cardiovascular disease incidence continues to rise, that demand is not going anywhere.
The market’s trajectory tells a simple story: healthcare systems globally are investing in getting cardiac answers faster, in more places, with greater confidence. The technology is ready. The need is real. And the numbers reflect both.
